Trial Profile
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Therapeutic Use
- Acronyms OLYMP-1
- 23 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2024.
- 04 Nov 2022 Planned primary completion date changed from 31 Dec 2022 to 1 Jun 2023.
- 04 Nov 2022 Status changed from recruiting to active, no longer recruiting.